Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors such as Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant plasma cells and other cancerous cells in the bone marrow.

The dosage of lenalidomide is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. The prescriber determines the appropriate strength, frequency, and duration of therapy, and any dose adjustments are made according to clinical response and laboratory monitoring.

Lenalidomide is classified as having unknown pregnancy category and is considered teratogenic in animal studies. It should not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is not recommended while receiving lenalidomide because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomid Zentiva. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and assists with any necessary import documentation.

The primary alternative to lenalidomide in many hematologic cancers is thalidomide, another immunomodulatory imide drug. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, and stronger anti‑angiogenic and immune‑activating effects. However, both agents share risks such as thromboembolic events and require careful monitoring.

Lenalidomid Zentiva tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Lenalidomid Zentiva is taken orally, usually with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole with a full glass of water and follow any specific timing instructions related to other concomitant medications to avoid potential interactions.

The most serious adverse events linked to lenalidomide include severe neutropenia and thrombocytopenia, which can increase infection and bleeding risk, as well as thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Rarely, secondary malignancies and significant liver injury may occur, requiring regular laboratory monitoring and prompt medical attention if symptoms arise.

Lenalidomid Zentiva is contraindicated in patients with known hypersensitivity to lenalidomide or any component of the tablet. It should also be avoided in individuals with active, uncontrolled infections, severe renal impairment without dose adjustment, and in pregnant or nursing women. Clinicians must evaluate each patient’s medical history before initiating therapy.